Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02527421 · ClinicalTrials.gov registry record · Phase 3
DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Primus Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT02527421 is a Phase 3 study that was terminated before completion, run by Primus Pharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT02527421, a Phase 3 study, was terminated before completion, sponsored by Primus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
Interventions
- DRUG DFD01 Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-08-19 |
| Est. Completion | 2019-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02527421
The ClinicalTrials.gov registry entry for NCT02527421 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Primus Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DFD01 Spray is the first listed.
NCT02527421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02527421 about?
NCT02527421 is a clinical study titled "DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis". To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
What is the current status of trial NCT02527421?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2015-08-19. Estimated completion is 2019-03-30.
What interventions are being tested in trial NCT02527421?
The interventions under investigation include: DFD01 Spray (DRUG).
Who is sponsoring clinical trial NCT02527421?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.